I'm LongbridgeAI, I can summarize articles.Revenue: As of FY2025 Q4, the actual value is USD 120.99 M.
EPS: As of FY2025 Q4, the actual value is USD -0.61.
EBIT: As of FY2025 Q4, the actual value is USD -13.72 M.
Segment Revenue
Fourth Quarter 2025 (Q4 2025)
- Total Revenue: $121.0 million .
- GeneDx Revenue: $119,492 thousand .
- Other Revenue: $1,497 thousand .
- Growth in exome and genome revenue: 32% (42% excluding a 2024 one-time benefit) .
Full Year 2025 (FY 2025)
- Total Revenue: $427.5 million, which was within the previous guidance of $425 to $428 million .
- GeneDx Revenue: $423,088 thousand .
- Other Revenue: $4,451 thousand .
- Growth in exome and genome revenue: 54% (58% excluding a 2024 one-time benefit), within the previous guidance of 53% to 55% .
Full Year 2024 (FY 2024)
- GeneDx Revenue: $302,293 thousand .
- Other Revenue: $3,157 thousand .
Operational Metrics
Adjusted Gross Margin (non-GAAP)
- Q4 2025: 71% .
- FY 2025: 71%, within the previous guidance of 70% to 71% .
- Q4 2024: 70.3% .
- FY 2024: 65.1% .
Adjusted Net Income (non-GAAP)
- Q4 2025: $4.4 million .
- FY 2025: $41.8 million .
- Q4 2024: $17,453 thousand .
- FY 2024: $9,405 thousand .
Net (Loss) Income (GAAP)
- Q4 2025: - $17,666 thousand .
- Q4 2024: $5,438 thousand .
- FY 2025: - $21,021 thousand .
- FY 2024: - $52,286 thousand .
Gross Profit (GAAP)
- Q4 2025: $84,268 thousand .
- Q4 2024: $66,205 thousand .
- FY 2025: $298,173 thousand .
- FY 2024: $194,397 thousand .
Gross Margin (GAAP)
- Q4 2025: 69.6% .
- Q4 2024: 69.2% .
- FY 2025: 69.7% .
- FY 2024: 63.6% .
Cash and Unique Metrics
Cash on Hand
- Cash on Hand: $172 million .
Growth in Exome and Genome Volume
- Q4 2025 YoY: 34.3% .
- FY 2025 YoY: 30.5%, meeting the previous guidance of at least 30% .
Exome and Genome Volume FY ‘22 - ‘25 CAGR
- 47% .
Exome and Genome Revenue FY ‘22 - ‘25 CAGR
- 61% .
Outlook / Guidance
GeneDx projects full-year 2026 revenue between $540 to $555 million, with exome and genome revenue and volume growth expected to be 33% to 35% . The company anticipates an adjusted gross margin of at least 70% and positive adjusted net income for the year . Exome and genome test result volume is guided to be 128k to 131k for FY 2026 .